These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
687 related articles for article (PubMed ID: 33324348)
21. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. Liu Y; Wei R; Hong TP World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081 [TBL] [Abstract][Full Text] [Related]
22. Promising therapies for treatment of nonalcoholic steatohepatitis. Noureddin M; Zhang A; Loomba R Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374 [TBL] [Abstract][Full Text] [Related]
23. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease. Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743 [TBL] [Abstract][Full Text] [Related]
24. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199 [TBL] [Abstract][Full Text] [Related]
33. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Sumida Y; Yoneda M; Tokushige K; Kawanaka M; Fujii H; Yoneda M; Imajo K; Takahashi H; Eguchi Y; Ono M; Nozaki Y; Hyogo H; Koseki M; Yoshida Y; Kawaguchi T; Kamada Y; Okanoue T; Nakajima A; Jsg-Nafld JSGON Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168769 [TBL] [Abstract][Full Text] [Related]
34. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675 [TBL] [Abstract][Full Text] [Related]
35. Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis. Kojima M; Takahashi H; Kuwashiro T; Tanaka K; Mori H; Ozaki I; Kitajima Y; Matsuda Y; Ashida K; Eguchi Y; Anzai K Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785012 [TBL] [Abstract][Full Text] [Related]
36. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Sugimoto K; Inui H; Fukusato T World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263 [TBL] [Abstract][Full Text] [Related]
37. Anti-diabetic drugs and NASH: from current options to promising perspectives. Smati S; Canivet CM; Boursier J; Cariou B Expert Opin Investig Drugs; 2021 Aug; 30(8):813-825. PubMed ID: 34214406 [No Abstract] [Full Text] [Related]
38. The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. Cariou B Diabetes Obes Metab; 2022 Feb; 24 Suppl 2():15-27. PubMed ID: 35014161 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744 [TBL] [Abstract][Full Text] [Related]
40. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study. Ooi GJ; Burton PR; Bayliss J; Raajendiran A; Earnest A; Laurie C; Kemp WW; McLean CA; Roberts SK; Watt MJ; Brown WA Obes Surg; 2019 Jan; 29(1):99-108. PubMed ID: 30229460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]